This article reports on results from a 4-week randomized, open-label efficacy trial on the effects of treatment with liraglutide, a once-daily human GLP-1 receptor analog, on insulin dose and glycemic control in patients with type 1 diabetes mellitus with and without residual β-cell function [NCT00993720; Kielgast U et al. Diabetes Care 2011].